Abstract P1-09-06: Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trialAmy J. Williams, Sibylle Loibl, Carsten Denkert et al.|Clinical Cancer Research|2025Cited by 1